# CoFlo Medical

> Develops injection devices for high-viscosity medicines.

## Why it is interesting

Viscosity can limit how a concentrated medicine is delivered. CoFlo addresses that engineering constraint, but a useful drug/device combination still requires formulation compatibility and product-specific validation. Laboratory demonstrations and financing do not establish clinical outcomes or regulatory clearance.

## Profile

- **Latest funding:** Seed announced; instrument composition undisclosed — USD 6 million; instrument composition undisclosed (November 19, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** seed
- **Status:** private
- **Industries:** N/A
- **Coverage:** stub
- **Last updated:** 2026-11-22
- **Latest funding investors:** J2 Ventures

## Key facts

- CEO Simon Rufer announced a $6 million seed round on November 19, 2026. J2 Ventures separately confirms its lead role.
- A 2025 SEC Form D reported $500,000 sold toward a $6 million offering. That historical disclosure is not added to the announced seed amount.

## Funding history

- Seed announced; instrument composition undisclosed · USD 6 million; instrument composition undisclosed · November 19, 2026
  Source: https://www.linkedin.com/feed/update/urn:li:activity:7529214203887337472

## Investors in our directory

- https://venturecapitaltracker.com/fund/j2-ventures

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 22, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/coflo-medical
